CJEU Confirms Settlements Can Break EU Law
In Ruling Related To ‘Pay For Delay’ Deals Over Paroxetine
Executive Summary
The UK’s Competition and Markets Authority has welcomed a formal ruling by the CJEU that settling patent disputes can break EU law by restricting competition and abusing a dominant position, in a case revolving around so-called ‘pay for delay’ settlements over GSK’s Seroxat paroxetine antidepressant.
You may also be interested in...
UK Reduces Fines On Paroxetine Pay-For-Delay
Fines imposed on firms including Actavis, Alpharma, Generics UK and Xellia as well as GlaxoSmithKline have been reduced following Competition Appeal Tribunal ruling that nevertheless upheld a finding of competition law infringement linked to historical pay-for-delay deals.
EU Investigates Teva For Undermining Copaxone Generics
The European Commission is investigating whether Teva “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.
Teva Under Investigation For Creating ‘False Perceptions’ Of Generics
The European Commission is investigating whether Teva has “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.